OSU as a Network Lead Academic Participating Site for the NCI NCTN
OSU 作为 NCI NCTN 网络主导学术参与网站
基本信息
- 批准号:10356923
- 负责人:
- 金额:$ 108.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-28 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAdvisory CommitteesAffectAreaAwardBasic ScienceBiochemistryBiological MarkersBiomedical ResearchBiometryBiotechnologyCEBPA geneCancer BiologyCancer CenterCancer HospitalCancer PatientCenter for Translational Science ActivitiesClinicClinicalClinical DataClinical InvestigatorClinical Oncology Supplement (K12)Clinical ResearchClinical SciencesClinical TrialsClinical Trials NetworkComprehensive Cancer CenterContractsDataDatabasesDecitabineDisciplineDiseaseEducationEducational process of instructingEducational workshopEnrollmentEnvironmentEpidemiologistFLT3 geneFacultyFosteringFundingGenerationsGoalsGrantGrowthGynecologic OncologyHealth PersonnelHematologic NeoplasmsHematologyHematopoietic NeoplasmsImageImmunologicsImmunologyInfrastructureInpatientsInstitutesInvestigational TherapiesKnowledgeLaboratory ScientistsLeadLeadershipLearningMalignant NeoplasmsMedicalMedical OncologyMentorsModelingMolecular GeneticsNCI Center for Cancer ResearchNational Clinical Trials NetworkNursesOblimersenOhioOperative Surgical ProceduresOutcomeOutpatientsPathologistPatient-Focused OutcomesPatientsPeer ReviewPentostatinPerformancePharmacistsPharmacologyPhasePhysiciansPostdoctoral FellowProtocols documentationPsychiatristQuality of lifeRadiation OncologistRadiation OncologyRadiation therapyResearchResearch ActivityResearch DesignResearch InstituteResearch PersonnelResourcesScienceScientistSiteSolid NeoplasmStructureSupport GroupsSurgical OncologistSurgical OncologySymptomsTherapeuticTherapeutic AgentsTimeTissuesToxic effectTrainingTranslatingTranslational trialTumor BiologyUniversitiesbasecancer clinical trialcancer preventioncancer therapycareercareer developmentcollegeconfirmatory trialdata submissiondesigndoctoral studentdrug developmentefficacy evaluationexperiencehigh standardimprovedimproved outcomeinnovationinvestigator-initiated triallenalidomideleukemiameetingsminority patientmultidisciplinarymultimodalitynext generationnovelnovel therapeuticsoperationpatient populationpre-clinicalpre-doctoralpreclinical studyprogramsrecruitresearch studyrisk stratificationrituximabsuccesstargeted treatmenttranslational scientisttranslational therapeuticstreatment trialtumor heterogeneityvolunteer
项目摘要
PROJECT SUMMARY
The goal of this application is to provide the infrastructure to support The Ohio State University's (OSU)
participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead
Academic Participating Site (OSU-LAPS). Faculty from OSU are integrated into the scientific and administrative
activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing
adult NCTN network groups using OSU Comprehensive Cancer Center (OSUCCC) resources to leverage group
resources. OSUCCC investigators develop and lead studies designed to enroll patients on multi-disciplinary
treatment trials as well as develop and perform correlative science related research studies, bringing special
expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation
oncologists, transplanters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory
scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame
the clinical and basic science questions whose answers contribute to improved patient outcomes and to
understanding tumor biology. OSU-LAPS will offer innovative NCI trials to the OSU patient population, support
scientific discoveries about tumor biology, find better treatments, and augment the quality of life for patients thus
improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1)
investigate new therapeutic agents, and their toxicities in Phase I to III NCI clinical trials; 2) evaluate the efficacy
and toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively;
3) develop multi-modal approaches using surgical, immunological, and radiotherapeutic therapies in optimal
combinations; 4) integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and
biostatistics in the design and execution of therapeutic protocols; 5) improve cancer outcomes through discovery
and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) understand
and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) improve the management of
cancer related symptoms, 8) form the next generation of clinical investigators by offering them formal teaching
and mentoring within the NCTN, and 9) enroll volunteering patients on trials.
项目摘要
此应用程序的目标是提供支持俄亥俄州州立大学(OSU)的基础设施
作为网络领导者参与NCI的NCTN计划的科学和临床研究活动
学术参与网站(OSU-LAPS)。来自俄勒冈州立大学的教师被整合到科学和行政
活动,参加会议,管理多个核心实验室,设计研究并在所有现有的
成人NCTN网络组使用OSU综合癌症中心(OSUCCC)资源,
资源OSUCCC研究人员开发并领导旨在招募多学科患者的研究
治疗试验以及开发和执行相关的科学相关的研究,带来特殊的
在血液恶性肿瘤和实体瘤方面的专业知识。我们的医疗,血液,外科和放射
肿瘤学家、移植者、精神病学家、病理学家、细胞遗传学家、转化和基础实验室
科学家、统计学家、流行病学家、护士、药剂师和临床研究协调员帮助制定
临床和基础科学问题,其答案有助于改善患者结局,
了解肿瘤生物学。OSU-LAPS将为OSU患者人群提供创新的NCI试验,支持
肿瘤生物学的科学发现,找到更好的治疗方法,提高患者的生活质量,
改善影响成年人的各种癌症的结果。该综合方案旨在:1)
在I期至III期NCI临床试验中研究新的治疗药物及其毒性; 2)评估疗效
和毒性,以更有效地开发协同组合;
3)发展多模式的方法,使用手术,免疫和放射治疗,
结合; 4)整合分子遗传学,生物化学,药理学,免疫学,
生物统计学在治疗方案的设计和执行; 5)通过发现改善癌症的结果
和教育的前和博士后学生,护士,专职医疗人员和医生,6)了解
并利用肿瘤异质性,充分发挥靶向治疗的价值,7)改善
癌症相关的症状,8)通过为他们提供正式的教学,形成下一代的临床研究人员
在NCTN内进行指导,以及9)招募志愿患者参加试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID P. CARBONE其他文献
DAVID P. CARBONE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID P. CARBONE', 18)}}的其他基金
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer
靶向免疫抑制腺苷治疗转移性非小细胞肺癌患者
- 批准号:
10593117 - 财政年份:2021
- 资助金额:
$ 108.37万 - 项目类别:
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer
靶向免疫抑制腺苷治疗转移性非小细胞肺癌患者
- 批准号:
10350636 - 财政年份:2021
- 资助金额:
$ 108.37万 - 项目类别:
OSU as a Network Lead Academic Participating Site for the NCI NCTN
OSU 作为 NCI NCTN 网络主导学术参与网站
- 批准号:
9902398 - 财政年份:2019
- 资助金额:
$ 108.37万 - 项目类别:
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心
- 批准号:
10374819 - 财政年份:2019
- 资助金额:
$ 108.37万 - 项目类别:
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心
- 批准号:
9894764 - 财政年份:2019
- 资助金额:
$ 108.37万 - 项目类别:
OSU as a Network Lead Academic Participating Site for the NCI NCTN
OSU 作为 NCI NCTN 网络主导学术参与网站
- 批准号:
10581614 - 财政年份:2019
- 资助金额:
$ 108.37万 - 项目类别:
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心
- 批准号:
10133005 - 财政年份:2019
- 资助金额:
$ 108.37万 - 项目类别:
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心
- 批准号:
10582677 - 财政年份:2019
- 资助金额:
$ 108.37万 - 项目类别:
Notch ligands in regulation of anti-cancer immunity
Notch配体在抗癌免疫调节中的作用
- 批准号:
8743193 - 财政年份:2013
- 资助金额:
$ 108.37万 - 项目类别:
Notch ligands in regulation of anti-cancer immunity
Notch配体在抗癌免疫调节中的作用
- 批准号:
9130120 - 财政年份:2013
- 资助金额:
$ 108.37万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 108.37万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 108.37万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 108.37万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 108.37万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 108.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 108.37万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 108.37万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 108.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 108.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 108.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)